<SUBMISSION>
<ACCESSION-NUMBER>0001193125-09-150742
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20090714
<ITEMS>8.01
<ITEMS>9.01
<FILING-DATE>20090717
<DATE-OF-FILING-DATE-CHANGE>20090717
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>PRO PHARMACEUTICALS INC
<CIK>0001133416
<ASSIGNED-SIC>2834
<IRS-NUMBER>043562325
<STATE-OF-INCORPORATION>NV
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-31791
<FILM-NUMBER>09950235
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>189 WELLS ST
<STREET2>STE 200
<CITY>NEWTON
<STATE>MA
<ZIP>02459
<PHONE>6175590033
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>189 WELLS ST
<STREET2>STE 200
<CITY>NEWTON
<STATE>MA
<ZIP>02459
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>FORM 8-K </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>Form 8-K </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Current Report
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>July&nbsp;14, 2009 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Date of Report
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Date of earliest event reported) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B>PRO-PHARMACEUTICALS, INC.
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact name of Registrant as specified in its charter) </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Nevada</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>000-32877</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>04-3562325</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>7 Wells Avenue </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>Newton, Massachusetts 02459 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of principal executive offices) (Zip code) </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(617) 559-0033 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Registrant&#146;s
telephone number, including area code) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Former name or former
address, if changed since last report) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;8.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Other Events. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">On July&nbsp;17, 2009, Pro-Pharmaceuticals, Inc.
issued a news release that the Suffolk County Superior Court allowed Pro-Pharmaceuticals&#146; (&#147;the Company&#148;) motion to dismiss the trade secret lawsuit prosecuted by Prospect Therapeutics, Inc. (&#147;Prospect&#148;) against the Company
and its former Chief Executive Officer, David Platt. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;9.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>(d)</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibits </B></FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">News release of Pro-Pharmaceuticals, Inc. entitled &#147;Pro-Pharmaceuticals Prevails in Trade Secret Lawsuit&#148;, dated July&nbsp;17, 2009. </FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">PRO-PHARMACEUTICALS, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ Anthony D. Squeglia</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Anthony D. Squeglia</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="98%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date: July 17, 2009</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>NEWS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>News Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px">

<IMG SRC="g68496ex99_1.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>PRO-PHARMACEUTICALS PREVAILS IN TRADE SECRET LAWSUIT </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Court Dismisses Claims For Lack of Prosecution </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B>Newton, MA &#150; July&nbsp;17, 2009 &#150; Pro-Pharmaceuticals, Inc. (OTCBB: PRWP)</B>, a developer of carbohydrate-based, targeted therapeutic compounds to treat cancer and fibrosis, today announced that the Suffolk County Superior
Court allowed Pro-Pharmaceuticals&#146; (&#147;the Company&#148;) motion to dismiss the trade secret lawsuit prosecuted by Prospect Therapeutics, Inc. (&#147;Prospect&#148;) against the Company and its former Chief Executive Officer, David Platt.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:3px;"><FONT FACE="Times New Roman" SIZE="2">&#147;Putting the lawsuit behind us is a significant event. We believed from the beginning that this lawsuit was without merit and are
pleased that the court allowed our motion to dismiss. This decision enables the Company to focus on commercializing DAVANAT<FONT FACE="Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
through regional partnerships with pharmaceutical companies,&#148; said Theodore Zucconi, Ph.D., Chief Executive Officer, Pro-Pharmaceuticals, Inc. We believe the termination of this lawsuit enhances our ability to raise the funds needed to complete
our Phase III trial. It also enables us to focus our resources on gaining FDA approval for DAVANAT<FONT FACE="Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and to reach our goal to
improve the quality of life for cancer patients.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:3px;"><FONT FACE="Times New Roman" SIZE="2">According to Pro-Pharmaceuticals, Inc., Prospect purchased certain assets,
including this lawsuit, from the GlycoGenesys bankruptcy estate and continued prosecuting the claims against the Company and Dr.&nbsp;Platt. Prospect informed the Court at the beginning that it would not seek monetary damages other than recovery of
attorney fees. Recognizing the value of the DAVANAT<FONT FACE="Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> technology platform, Prospect sought the Company&#146;s intellectual
property. The trial in this lawsuit began in March&nbsp;2009 and evidence concluded in April 2009. On May&nbsp;15, 2009, prior to the court&#146;s rendering a decision, Prospect announced that it was liquidating and had assigned all of its assets
for the benefit of creditors. In response, the Company moved to dismiss the lawsuit on various grounds, including failure to prosecute. Prospect&#146;s assets, including the lawsuit, were auctioned on June&nbsp;29</FONT><FONT FACE="Times New Roman"
SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT FACE="Times New Roman" SIZE="2">, and the new owner of the assets elected not to prosecute. At a post trial hearing on July&nbsp;14, 2009, after
hearing argument, the Court ruled from the bench and allowed the Company&#146;s motion to dismiss. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">&#147;I want to thank the outstanding team of new and
continuing directors as well as the management team who accepted the challenge in February of this year. We assembled an exceptional team despite the litigation,&#148; said James C. Czirr, Chairman of the Board, Pro-Pharmaceuticals. &#147;Despite
the litigation risks, all of the team members were willing to put their notable business and scientific reputations stand in support of the Company&#146;s commitment to bring its life saving and quality of life-enhancing products to market. We also
would like to thank our loyal shareholders who have stayed with us and supported the Company&#146;s mission. We believe that their patience will be rewarded.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px;padding-bottom:3px;"><FONT
FACE="Times New Roman" SIZE="2"><B>About DAVANAT<FONT FACE="Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:3px;"><FONT FACE="Times New Roman" SIZE="2">DAVANAT<FONT FACE="Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>,
Pro-Pharmaceuticals&#146; lead product candidate, is a carbohydrate polymer specifically formulated to interact with galectins.&nbsp;DAVANAT<FONT FACE="Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>&#146;s mechanism of action is based on interacting with galectins which are over-expressed on the surface of solid tumors.&nbsp;Current research indicates that
galectins affect cell development and play important roles in cancer, including tumor cell survival, angiogenesis and tumor metastasis.</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Pro-Pharmaceuticals, Inc. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Pro-Pharmaceuticals, OTCBB: PRWP, is engaged in the discovery, development and commercialization of carbohydrate therapeutics for advanced treatment of cancer and fibrosis.&nbsp;Initially, the product pipeline is focused on increasing the
efficacy and decreasing the toxicity of chemotherapy drugs.&nbsp;The Company is headquartered in Newton, Mass.&nbsp;Additional information is available at www.pro-pharmaceuticals.com. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">FORWARD LOOKING STATEMENTS: Any statements in this news release about future expectations, plans and prospects for the Company, including without limitation statements containing the words &#147;believes,&#148;
&#147;anticipates,&#148; &#147;plans,&#148; &#147;expects,&#148; and similar expressions, constitute forward-looking statements as defined in the &#147;safe harbor&#148; provisions of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are based on management&#146;s current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in such statements. We caution
investors that actual results or business conditions may differ materially from those projected or suggested in forward-looking statements as a result of changing conditions. Readers should not place undue reliance on forward-looking statements. The
forward-looking statements represent the Company&#146;s views as of the date of this news release and should not be relied upon to represent the Company&#146;s views as of a subsequent date. While the Company anticipates that subsequent events may
cause the Company&#146;s views to change, the Company disclaims any obligation to update such forward-looking statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Contact: Pro-Pharmaceuticals,
Inc., Anthony D. Squeglia: 617.559.0033; squeglia@pro-pharmaceuticals.com. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">DAVANAT is a registered trademark of Pro-Pharmaceuticals. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g68496ex99_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g68496ex99_1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`-@%\`P$1``(1`0,1`?_$`+P```$#!`,!````````
M```````'"0H"!08(`0,$"P$!``$%`0$!``````````````4"`P0&!P@!"1``
M``<``00!`P,#`@0#"0```0(#!`4&!P@`$1()(1,4%3$6%U$B"B,808$R)'$S
M=4)RM#5%M28V-Q$``@$"!0,"`P0&!0D%"0```0(#$00`(1(%!C$3!T%182(4
M<3(5"(&1H;$C,_#10K(6P>%28G)#4W,TDL*S)1?Q@J+2DZ,D-3;_V@`,`P$`
M`A$#$0`_`)_'3#!TPP=,,'3#!TPP=,,:E<RN;G'C@ADKW7N0MT1K\68SAE5*
MM'%2D;SHE@10^NG6J-6P71<S,F<#%%503),V29@5=+(I=S];)Q?BF]\OW(;9
MLL1>3(NYRCC7_2D;HH]AFS')03ECX2%%3B!7R6]M/(GV/<KLS_<;EQF>#5:Z
MO);,\.KTFHHQB7;2#FDXVV7:;0(U6M]_(@H(E<B5)G'"<Q&2*?DHJM[4X1XX
MV3@]B>P!<;O(FF6=AFP/5$4UT1_#,M_;)R`UGE3L>/W1&5$']]<29>`7MN,0
MT-C?+2;[@86\94=P>B4I1,(E1:16G'*!2IF'X(G.`'B(]OO0*/DY'D/D?PQ7
MN;YPR/W:2T'ZRT'^6+_Z?HF-8XWS3[MAO3?!93^P2?\`S_\`:]\2'F[AN[;H
M.FJZ+EJY12<-G+=4BS=PW6(51%=!9,QDU454S`8IBB)3%$!`>W7F=E9&*."'
M!H0<B".H(]",=-!#"HS!QW=4X^X.F&#IA@Z88.F&#IA@Z88.F&#IA@Z88.F&
M#IA@Z88.F&#IA@Z88.F&#IA@Z88.F&#IA@Z88.F&#IA@Z88.F&#IA@Z88.F&
M#IA@Z88.F&#IA@Z88.F&#IA@Z88.F&/.5VU,H1$KEN950#"1(JR8J'`@`)Q(
M0#>1@(`_/8/CJHHX&H@Z1\,*''>(@4!,80*4H"(F$0```/D1$1^``.J0"<AU
MPQUD714'Q3624,`>7B10AQ[`(`(]BB(]@$0ZJ*LN9!`PQV]4X8QU2WU)&?3J
MBMHKJ5H6(51&MJ3<:2?53,B9P51.',Y"1.0S<AC@()B`D`3?H'?K*%C?-;&]
M6&4V8ZR:&T=:?>IIZY=>N*M#Z==#I]Z98R+K%Q3CY-W.CD9MW)WE!KE]W>^3
M5XLD-?[U3:^C(&^VAZ=4Z[;YB,BJM4X!`$XVNQ#-!H45$T$RG<K^2RYE5CF4
M']&>([)M.P<?MK/:(4A@>&-VIFSNR*2[MU9C7J3D,A098QB:FIPF_&O_`/NN
M;_\`K+S_`.Q2W6PR?<.-?Y3_`/SUU_RQ_?7#S8@`AV'Y`?@0']!#K'QPS$D_
MT=Z]HUMKNQ9;9[3(3U)S9M1GE$BY0_W:M8)8EK4E*1<8_5\GB<(<8E$Z+,QS
M(MC^?T@(!S!UY9\_[+M=G<V.[VD*QW]TTHF9<NYH$95F'37\Q!;JPI6M,=5\
M?7MU-%/:3.6MX@A0'/3JU5`/6F0H.@],/U'703'Q4623-V[^)U"%'M_7L80'
MMUYU"L<P"1CH],=OZ_(?(#U3AB@JB9C&(4Y#')_UE*8HF+_[Q0'N7_GU]H0*
MD988`4()Q3`Y!4*`"8@&`3E`>W81+W\@`>_2AI7TPQ4(@4!$1```!$1$>P``
M?(B(C\``!U\PQP4Y3E`Q#%.4?T,40,4>P]A["`B`_(=?2"#0]<,<'532`!44
M(F`CV`3G*0!'^@"80[CT`+=`3ACDAR*%\DSE.7N(>1#`8O</U#N41#N'0@@T
M.1PQP=0B8>2AR)E[]O(Y@*'<?T#N80#N/0`G(9G#%1C`4!,80*4H"8QC"``4
M`#N(B(_```=?.N0ZX8X*8IR@8ABF*/R!BB!BB']0$.X#T((R/7#`<Y$RB90Y
M2%#MW,<P%*'<>P=Q,(!\CU]`)R'7#%77S#!TPQ015-4!%)0B@`/81(<IP`?U
M[")1'L/;KZ5(Z@C#%!W""9A*==$A@[=RG4(4P=P[AW`3`(=PZ^A&.8!(PH<=
MA3%.4#$,4Y1_0Q1`Q1_X?`AW`?GKX00:'KAC@BA%`$4SD.`")1$A@,`&#]0$
M2B(=PZ$$=<,!%$U._P!,Y#^(^)O`Q3>(_P!!\1'L/0@CJ,,=8NFP"("X0`0$
M0$!63`0$/@0$/+X$!Z^Z']C^K"F.TAR*%\DSE.7Y#R(8#%[A^H=RB(?'7P@@
MT.1PQP10B@>29R'+W$.Y#`8.X?J'<HB'<.A!'7+#'"RR+=,RRZJ:"1.PG56.
M5-,@"(%`3'.)2E[F$`^1_4>BJS'2H);V&&!-5)8OFBJFJ0>W8R9RG+\@`A_<
M41#Y`>_0J5-&!!PQR=1-/M]0Y">0^)?,Q2^1OZ!Y"'<>@!/05PQ7U\PQ0"B8
MG,F!R"<H`)B`8!.4![=A,4![@`]^OM#2M,L,5]?,,8VQN50E)EY7(RUUN1L,
M?]89"!8SL6[F6(-SD3<"\BV[I1\V^@HH4I_,A?$Q@`>PB'67)87T-NMW-#,E
MJU-+E&"&O2C$4-?2AQ44<#400I]:8R3K$Q3@Z88H.H1,/)0Y$R]^W<Y@*'<?
MT#N80#N/;KZ`3D,SABH1`H"8P@!0`1$PB```!\B(B/P``'7RA.7KAC@AR*%\
MDSE.7N(>1#`8O</U#N41#N'7T@@T.1PP$.10/),Y3E[B'D0P&#N'ZAW`1#N'
M0@C(Y'#`<Y$RB90Y2%#MW,<P%*'<>P=Q,(!\CT`)-!F<,<$435#R3.10H#V$
M2&*<`'L`]NY1$._8>A!&1%#ABOKYACY86.QW#M+UL:]JEAV[0:G[,*_R&A8G
MBY6J'I-]_?,_613S7Z:1*7%/%6+>)77E)TZ4L7Z#T7S1)%%10Q2MEOV8WZ;G
M9\LV.RVNW6L_B*7:W;<9)H(>RDG\?_>L`2P"P@Q9IH8LP`)=>E3-=#<$B"*=
MN,9UD@4KGZ^_3+XXGC\D9?7Y+T=:U-[FB_BMR>^N:<D=42<%4CY=GHR^%&7M
M8OTDP0483)9TRPN4R@3Z+GS*`%\0`/S9XI!L47YBK*WXX5?CB\K1;:GS*8!>
M4CT]=2:*:2:U6ASQI5N(AO2+#G!]0-/V:LOV8AD812\DN^.>NI/URV?D-.>W
M,^KP\SNW[!G-9DZ#1*.2V6YJ[F=+?2Z:U!JL8QBV4,HN1H<6"\6L[*_(H!RD
M'WWR3<-\V[?N5'RK#M<?@[Z)DL^\ELLTTW;B(6`+2:1BQE`+#6)`AB(H3C;9
MY)8YI_Q`1C:]-%J%J30=/4]3USK2F)JWN?YG7G@?Z\=CW+-B(%U)R-:S:@RR
MR1%VU8M&@R:4&-O!JL0Z+IS5HP[I\S15*9%1ZBB54IDQ.4?S[\`<`V[R3Y2L
M..;O7\&'<GF4&ADC@4OVJC,"1M*,1F$+%:&AQJ&T6:7U^D$G\K,GX@>GZ?W8
M9]@_\<[$+9P7)L<UI>Q6+V'6S*";NAR-=Z?8DED=FEJZ6^Q\$5BO($9FJX2Z
MQ(Y:17/^6.4RCTKE$XD23[K<_FKY%8^1SL-O:6$7BV"]^C-B+="#:J_99ZA:
M]S2"XC`[0RC*,*DRQY!,E[V@J"P#:=%!]VM*_;ZTZ>E,.<^@OEII/,+UOYK=
MM@E)"QZ3G-KN.*6>X3$BM*S5S/0UH]:%LD[(.55W+V>=5N;9)/G"AS'=.T%%
MQ_\`-ZY!^9CA&T\$\L7>W;$BQ;3=P17<<2J%2+O!@\:*``$$B.44"BJ0OIB-
MWNUCM-P9(LHV`8#VKZ?K&/G<\C6P,^1G(9F'F`-=[V=L'U0\5.R&EV=(/J!V
M+XG_`+?GX#L/7JO8VU[)9-[V<!_^TF-?/7#M/"3U>5W0H["M]5]AO!:D.[5$
MHVM3&[IIGXK5JXK(1<DV/7+!!"K]1I.L!.)ED_#X*41#X^>N=;MY0GVZ_N-N
M78-YG6&5D[B1$H^EJ:T.DU5J54US%#B,WRS%[M$]L98X@Z`:G-%7Y@:G]5/M
MQMGR!Q-I@]PBJFRUW*]F3E*VA8367(YTU@K\:HO)R<;^#D79B%^C,I%C@<&3
M#O\`Z"Z8_P#'K9.*<E?D]I+=26-W8&*0)HN%*LU5#:E!`JN=*^^.*;KMB[7,
MD2SPW`9:UC-0,Z4.9S]</)>AG_\`8.3/_I&5?_&7SKBWYB/^FVK_`)EQ^Z'&
M[>.OYEW_`+,?[WQHK[)ZKPCO?O3F:[["]%_CWCNR]?M;GF,D[TZWYFS-I#*_
M2R,"W9R%1D&3^1EEH)S*'28E!3[H4O\`H4,0I1ZIXEO?(>V_EQCN_%UI]5RE
MN3R(RBWBN#V#`I<E95*JH<1@OEIKU`)..^[>UXFRZK%=4_?/H#E3/K\:9XWA
M_P`;*SZ?/\?.4$>:SZ/>.)%7Y.VZ!X3W+5#2+BT362M#O$W96CR7*F_7@&Q4
MXXY4RD*U;2:S]%(I#$523YU^;.SV>VY1L\HAM+?F\VSQ/NT5OI$:7)H14+\H
M<_.*UU-&(V)(()PN0+$L\9HHNC&#(!TU?TK^BF&W<)]E.`>O+W#>X"=Y(/-3
M<PNCZG7X&F-:%3Y:_@V=UE[*OY<'C)L^1)#(BA,H?2-X]E1\@^/#YZQR3Q+R
M;RCX(X+;\36S%Q:6;O*9I5AJ)`JK0D'4:H:^V7OB0GVZ>^VFU%OIJ%J:FG49
M?NQL;ZJN5>><S??1SOW_`!YY=3Y;=^(='+7&5WAW]7ET'-9D,'JLP=S5W;MT
M$?WEXEQ](_ZK(B"GQYB'6K>9^%[IP'\M7&^,[\MN-YM]\E[AB82*1(+R1:2`
M#5\K+4>AR],8^Y6KVFR00RT[HE-:9]=1'[\.!_Y!?(6?R[@ZUP/.'+\=EYO:
MC2>,-`CH,RXV):+MTLU6OCN)0;*(K*F6KZ(1`]CE[*S*7R'<!#E_Y8.+6V\^
M1&Y+NP7\`X[9R[A,STT!HE(A#$U`HY[O3I$<8.QP++>=^3^3"I<^V73^O]&$
M`_Q_;7<<!L_.+U6Z]87DW?.'&U/K5GTI*B\3>6G'M).1=";C6[U9PHE$*2R;
M>6`@'.5+]RID`Q@`!ZV?\SEE8<FL^.^9]BB6/;=^V\1SJM*1W4&11B`*MIU1
M=!7Z<F@QD;XB3K#N<0HDR4/P8?TI_P"[BW?Y)1LS-7_6XRVZ=>US#I/G/5V&
MU2K*8GX(S3*7%8DR7QRK)5@?SS5-K6A<J?4:%.Y3\?)(!.`=7?RFC=Q=<LDX
M[$LO(DXY(UHI5'K<B1>R-,GR&LFD4;Y3_:RPX_W-5P81680G3T^]7+KEU]\(
MAZ8*?667LRY+6CU_N^0K[U7.\.:L6$[ICG2E,ILF_)3E1;./XP=:>0)FS'C6
M["2'[XP&>(I*+I*J?;'9E-L7GZ^NY/$6T6?DY=K7S.NXDLEN(/J8[(I*1]0+
M?Y(]1:/Y/N$A2!K#TO[NS';XUOM`W,/T%*A<^M,AZ?#]-<+3_DQ,[QK&3<)^
M(^;.'Z=SY&\HW1HYO&N%V[ATA0,WLOU@5,@[9&,S;.[BW55\E"D*4GF(_P!O
M6O\`Y1I-NV3>^0\XW8*;#:MG&HL`0#-/'TJ#F1$P&5<Z>N+''FCAEEN9?N)'
M3]9_S'&D.H\^+KS,](?!KC)F]B<.N4O,?2JCPMMY&JCE>;8M,,?1[C2[9(BP
M6-*&1EJO%5YV_43_`+U&D\J/?Y'OT39O&FW\!_,/R/E^[1!>&[#:2[K%4`(3
M>*P@B74--5D:=4!R#0C&;'91V>\S7$HI;1*7'M\P-!_>I]F'<_\`'%TUSHOJ
MEQ>.?O5Y"2RRZ[#EKYPZ66<.1_#Z+.6&-376<&.N<R<':&H%\Q[E(!0_0`ZX
M;^:W:$VKS3N$L2A8;VWM;@```?-`B-0#+[\;=/6N(OD$8CW-R.C!3^RG[QC2
M_P!_)M.YK<A^*'JEP.:=,K;9*IK'*O3SL';E))K'T"A7)KE4/,*1ZJ:S=&PS
MD=*-BE5,4GW;MB?M\E'KH'Y9AM'C[BV]^:>31AK**:VVZWU`5+331&Y9=61*
M(T;5&>E9![XS-C[=G!+N<X^0%4'Z2-7ZA3]N'+O1KRL>\L_6_AEAL[QPXT[(
MV3OC[K"$AY!+-[EDP-H)JXERJB+C\G-4XT5(.#*`!S.'2G?Y`>N1_F+X7'PG
MRQN5K9J!L]\PO;8K]TQ7-7(6F6E)>XBTRTJ,1V\VHM=P=5_EO\R_8?ZC48;/
MY+*OO:[[H;3Z[[7L>CT?B+P[Q)30-'HN2VJ:HTCL>HRG[&/*1%IL$2Y346BX
M$+Y&MR`=(XM2LGI&PI*O#+DZYQ)8_"O@"'RE96%I<\YW[<>S!-<QI,MK;KWM
M+1HPR9^S(QH1JUQEZK&%,A`!MNSB^5%-U,]`3GI`KT^VA^VN?3#YG"SU^\=N
M`4+H];XYL;Q$U[3K+$VN=B+E?;#?TF$I$0J4$@$&_M#E_,LVB[5(#JIJ.5P%
M4>Y1*7L4/.?D#R=RKR9<6MWRIK=[JSA:-&BA2&JLVLZUC`0D'($*N76IJ<0M
MW>SWK!YR"P]A3_-Z>E/?J3B(+S\LW!&%]Z/-DOL2C-OLV-?Q3C*=%A\8E-"0
ME66CFS7(E$WK]O0K'7WJ<2-;_(%,*AS(BN<@B43]C![H\96GDB?\N/'CXL?;
MH=^^MNN\UTL)4P?4750IFC<:NYHZ"ND'.F6-KLEO3LL)L-(FU-4L!TJWN#ZT
MQ,&]>3+CTRX6\?!XI1EQA^/$G2E+#ED;H#N??7)K7[1.S%C5+/N+1)2\\+T\
MI*.#>#ARJ*9#%(4?`I0#PGY1DY1)S_=/\:/!)RE+@)<-"$6(O&BQC0(U5*:5
M7HHJ:DYDXU.]:9KES<4,U<Z"GH/2@_=7WPUG_C3.W;W@QMBKUV[>JEYS\C4B
MJO'*[I0J2;>A`1(JCA10Y4R=_@H#V#N/]>NR_FVCCC\B[<L:JH_PY8G(`9UG
MSRQ);^`+Q`/^$/WMA)_\:%\^>U'V2B]>O'HH<^M!10%XZ<.A11+%M!*DD*ZB
M@IIAW_Z2]@ZF_P`W$<<=]Q/MJJUXS`30`5.H^V+W(5"M;T]81C4#VK^KGB%D
MG-#UIP=&K>B14;S9YG6:L\A&ZFR:<]"SPUAFZC+R;6&%W9UAJ)E7UJ>&(>,^
MV.F50"E$`(7MO7A?S'SG>^`<MN-QEM7EX]L$<ED?I;<=MT255+TC'=H(TRDU
M`T^)QD[9N5W):3ZBI[,55^499-\,^@ZXE.<6>)^+\+\=;X?@D/.P6>L)JPV5
MM'V*W66[299:R./O954\]:Y*5EU$E7!0$B9EA(F'P4`Z\:<RYKO_`#_?CR+D
MLD<FZ-&D99(HXETQBBC1&JKD/6E3ZXURXN9;N7O3&K_93#/?^,V[=O?7I>EG
MKMV]6#F!R#2!9XY7=J@FFO5`(F"KA10X)D#]`[]@[]=V_-S'''Y1MUC557\"
MLC0``?[WVQ*;^`+T4_X8_>V-)8W%'/O"]J?.:C\H-*TN`XK>ONR161YOA>97
M&0IC*S6):P62&D;5:'C5!R#A:<>4N27>.$OHR0H+LFJ*Z*+8WU.AS<@3\NWA
MCCFX\/M+27FG*(FN9[RXB64QH$C=8XP2*!!+&JJ:QU$CLK,XIG&4;-MD+VRJ
M;J<:BQ%:"@-!]E1\.OOB1YPQX48?P,RN9QO`6]O;4B:OU@T5="ZVV1NLLWFK
M$SAXY=DVFY?RDAAV$?`MD6J2QUE"%((F4.<QC#Y1Y_Y!Y%Y*WJ/?N3&`[C';
M)`#%&L2E$+L"47Y=19V+$`#.@```QK]W=S7L@EGIK`IEEZD_O/V>V6(G?OP5
MVKGOS#V+#./TU+%J'J]X@6#D)IA8)[(D-(:%:I&J3D["1ZD2LD4]G89Y]@Y:
M$4$QTQCI`I0\NX![7_+0O'O&G!+#D?*(T^NYCOJ65OK"_+!&LB([:A_+:?6K
M$9'7$2:8VC8^S8VJ33@:[F4**^PK3]%:U^T8D_\`JZY6H<T^!O'#?UGR3VTV
M*A,:]I'TUBJJ-].HYU*A?/N`+\HB_L,,L]2*/R+9TD;Y`P"/CWS'PIO'_DK=
MN,*I6RBN2\&5*V\W\6&GOI1PA_UE(],:WN5K]'?20?V0U1]AS'[#AJ/A2\>J
M?Y'GM89JO7BK-#CQCYT&:CIPHT0.>'PWR.@U.H9!$QNX]Q*4!^1_J/7:O(4<
M8_*CPN0*HD.Z7-305/S7G4]3B4O`/\/VI]>XW[VPX![L(OD_->M;D;%\1D;>
MXUEW$5\KM#/EG2-[7SE*S12^FH5/\<LA,.)5>F).R&08"+]PV,JDW*94Y2CS
M'\O<W#[?RUM4W.#`-D61Z&8`PB?ML+<R:@5"B4J:O\BMI+$`$XP-G-L-PC-W
M3M5/7I6F5?TX9L]`L;Z>)G1*=8L,A],S'V*4W+G]7TZG;G=[<A:[;+R,2U+J
M4Q4H.1F#5"UMC/8X[I1%JU0DHQH)3KM$``Y^N]?F:E\[V^USVO(Y+.\\5SW@
MDMY;.&(QQ*K'Z=975>[&:,%!9C'(U0KMD,2V^_BH0]_2U@6^4J!0"N0/J/3X
M$]#B77UX<QJV#IAB-O\`Y2[QXR]<5%68O'C%8>7&.IBLR=.&:PIGK&F^28JM
ME$E!3-V#N'?L(@'].O6/Y-HXY/*]RLBJR_@=UD0"/YEO[XV'C8!OVK_PF_>,
M.J^P555+UH<Q5DE545D^&6VJ)K)*G2634+C]A,51-9,Q5$U"F#N!@$!`?D!Z
MXQXO`;R[L*L`5._VF1Z?]4GIB,L/_P!C#_SE_O#$0[_'HYCZ+Q!U*G\>.1CZ
M2@N.WL'ITG?..-WMLR<]81UVIS,UG3E*/F9!T=K'A=9"LK0+YN<Q%$Y=K$]P
M`CL#G]S?FCX%M7.MFN.4\45)>5<7N%AOH8T_B&VD1)P6115NTL@F1@"#$T_J
MA`VG?K2.ZC-Q;YW$#4<#KI-#^RM?L)]L/Y_XV+EXZ]8594?N7;IR&\\A4CJO
M7"[EP`):-(D*F91P=17LF`=@`1^.O,WYLTC3S!,(@JI^&V1R``S@'MB"W\`;
MB0.FA?W8;>P;(6_OA]AW/6T\I-1T\O&#AEH,3C&+X5EVA6"BUJ6!&WZ!%-[3
M85HQNU7>JS+6A/';QPG]K*'6DTT"."-V:13=8Y+OC?EM\6\:L^&V=G_C#?[5
MKNZO+B!)I%K%`QC0,2!I,R*BG5&!&6*%I&.)&>7\%L(!;*OU,JEF8BI&0R_1
M6GMETS.),?#3AGC/!/'E,.PH+@%'5N5FO)AO-J>7&>_,6E1H+U(TV_22=JL&
M;=@@@V(IYG(BD'D<YQ,<?(O/>?;_`.1]]'(N2=C\1$$</\&,1)ICK3Y`2`26
M):F53D`*#&NW5U+=R]V:FNE,OTG_`"_Y!EC:_K2L8V([7HE]4UAX8XE=%N87
M'O$B<BQW&1ME!OA6E"TVWP5(3IM080I82]H,'LC6_M+`WE3D;MUT3D,L90?_
M`#`Z]3_F0\TVO/\`D-NO!-TW'_"OX<L<T-9K>)YN[*SZX2P62J&,%F!!H!Z8
MG]ZW,7<P^DD?Z?10C,"M3Z>N5,.[\[,INNZ\+^4^,9NQ9R=_U+!=0H=,CI"1
M;1#%]9;/492(AVKR5>"#6.;KOG1"G64$")E'R'X#KAOC?>MOXYS_`&;?]V9D
MVRRW.WFE95+$1QRJS$*,V(`-`,SB*LI4@O(II/Y:R*3]@.(VV'>HCGMPBK'K
M^Y4\2JS3&/+?-*O)Y)SDX_*:;"0%"WK-%[O;)J+D7=K^H>K25F:UATU9F7/Y
MJ).DXUVD`JL%P7]9<C\Y>-?(=YR?AG-YKAN$7<RW.T7HMW>:SN!#&C*(Z=Q8
MS(&<+D"IE0T65=,_-NMG>&:VNB?IF(:-J$E305IE6E:GTKF,JY2`/8OPMBO8
MEPLTOC987846Q72)@['3)N1(E)DH^EUAXTL-:6EB1B[E!]&IR3<T?)?;'5\V
M+E<4!,?Z9NO,?BKR!-XL\@6G+;5?J;6W=XY46J]ZWD!20+J`(;2=<>H"CJNJ
M@KB$V^\-A>+<+\R@T/Q!R/\`6/CABNOP7^1VCQ28^OTW&KCI%MDJ"3`PYBR6
MSP#]XPR<80:=^</`L[*YDW=H:U@X))R18<7?TB`<8X7O=;KT?=7/Y46YJWDX
M;ONKL;GZW\+6U=0;G7W=&LQA1&9,S'W=-33N]OY<33-L'U7U_<D^]J[>D_>K
M6G3I7TK^FF'\?7=PIIOK[XD95QBI[U*<7IT<YD[O;R-/L5+OHEB<&E+?:#MA
M.HH@W=2*OT&:1S&.A'-FZ)C&%/R'S1Y3\@W_`)/YQ>\POU,:SL%ABK7LP(-,
M4=?4A?F<C)G9FH*X@[^\>_NFN7RJ<A[`=!_7\<?,5Y>-OLN6_*MGW.(M>2^]
M(F^J7P5`Q=6M@B"A!`!(?^[].O<'&FU\;VYO>PM__!3$4>I^W%FXUHI#N^;F
M%),3#,O1$PD*)N_X*6^>_;OU,NS:#F<:_P`I_P#YZZ_Y8_OKAYX"@4.Q0``_
M7L```=_^76,23UQPS$@?T,_,_P`FQ#Y`L3E("(!\`(N[X(%$?T`1#Y[?TZ\V
M?F)_Z;:?]NX_=#CI?CK^9=_9'_W\+3IGK6E=Q]S:O*[;\0RC6N)S7AS$9S$%
MT5*I7(K7;(2^DFHQVGGDZ@^7!1A".714I`R`I%!8Y`'N<0ZC-H\M0\<\!#A7
M'=QO;'FK;\T[=@RQ5M'AT,.^A`S<+5*UR!],=JBW$0[3]+"[)<]VN51\M*=1
M_7A[:O5RO5&#BZQ5(*&K%;@V2,;"5ZO1;*%@X>.;%\&["+B8U!LPCV2!`[$2
M13(0H?``'7GJZNKJ^N'O+V22:[D8L[NQ=V8]69F)9B?4DDG$.S,[%F)+'J3F
M<,G<!N"N^85[+_:+R5U>I5EID7*"UU&6QN7;62"GY.7:1$E/.'RDE!-C*R%>
M.5!\D/BX*03B/8._CUZ#\E^2.-<C\1\.XELL\QWS9X95NE,;HJEE0#2YHKYJ
M?ND_MQ,7M[#-MUO;1D]R,&O7V'P_=7%[P#A-O>=^[+FAS4G:O78[CMLW'3/\
MYSZ>866%6F7]IK[+&DI1J\J+4P2D4W(M3I#LNJ0"*?3*("/U`ZQ^3^0N-;K^
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MO&/[G$P2C"*D&K8`7<H&AC(E$"*I%";Y!YVXAY(\0;IP[D]E9[-OD$\<^VQV
M-NXMVD4EF!`U+$SZI$9OE4]T-U4G%R;=H+W;GMID2.0&J!0:5'PH<SF#F.M<
M;W^V?A+I_-"Q^OMG2J/5+_0<9YFT?3]]@;A-1$;%N,9;-%HRXMS1LL<O[E![
M%NE43L$0,LL0X@`?/<.;>$O(6S\`M>3R;A<S6NYW^P36]F\2LS"Z)U1'4O\`
M+HP!#F@!%<86V7B68F+$J[Q$*17[WIT^-,(EZ\^$O-'UN<N]9P^B_2UKU9Z6
MYD+CE*T[HT:%VXT6F2-(32E=CJI..BRDM75WZBL<^^Q\BO`.RDNQ702":NP^
M4O(?`/+/!['D6Y5L?,MHJQ7.B!NU?QKI0.TB#2KA:.FO[E)(<T[16]?WEIN%
MLDS_`"[BHHV1H_0>@I\<SEF.E,+ORTXD;OO/M-];>ZQ];C'/&CBC`[K;+Q9'
M-FA6T@STF\U=>%JK!E4UW99R4#[J'CSF<(HF12!01,8!((=:WPGG'&^->&N6
M<;EE<<MWJ2SCAC$;D&"&0/(QD`T+DT@TD@FF0SQ8M;J&#;KB`_SY=('7H"/T
M="?7]^&Z^$OI5V;C7[>+YODRC!!PCS6<W/5N+<4A:F$@K$:%O<;6H>3BDZ,7
M_OX!2M03Q^Q%ZH4"KI0S$2"/]O;JGD+\P.P<M\&VW&;<R?\`J%=QV=MN+&-E
MU06;2,K=[H_<<(^@'(RR5]<2-YO$5QM0@%?K&"J^74+4]?B:9?$X<"].W#'=
M.#$!S.R;4(2%B\UM7,;2]:X\O8>RQDX:5S&Y(L&;%60CV*AG%=>HM:^T$[9P
M4B@&4$.P^(B/,/._/^.>1KG8-[V>21]V@V&WMKT-&R:;B(DMI8BC@EVHRU%!
M\:8C]UNX;UHI8Z]P1!6^T9_O)]\-[!Z7^2_,?G;S/YA\J-IV_B"XLETB:9QH
M4XTZQ4FUOE\.KS%:!9$M<Y!!-+P;)U%U^)=#&`=`ZD@Y=*+`82ICUU'_`-?^
M(\#\;[!P3AFW[=OJ0V[2W_U]M*8ENW(<]M'T!R&>5>Y0@(J!2*G$A^+V]I91
M6ELB2@"KZP::CGD#3U)%<\J8V;]3?KHY*>M7E;S%SHTFZTOA-L#.F:%F6KVN
MXUU[I3G6(MFR0LQ+?5F!63TLC.IV!^BZD4VY4G00K50W]RP]M0\V>5>)>6^%
M[#NNA;3R%8-+!<6T<4@@%LQ)C[4C5&E-"%4+$KW7`R7/&W3<+?<;:*2@6[2H
M(`-*&O0_"@IGZGVPF_-?@9S[P[V0%]G_`*SX7-]7M&ET!//.0&!:5/L:@PG6
M<5"0T8G)L):1FH!J^:3;6J12GBB]:/6,M')J@#INY<)DEO'ODKQGR+Q/_P"C
MWER2[LK.TNN_97L"&4H6=VTE51RI0R2#-&1XY"/D9%)N6=]8S;?^&[B655:J
ML!6G7X'W/PH?3#J'!'2_8+IT-I,QSTXYY)QP=I34!_$=8S31":'+/J^X8/S6
M(;Q(-)J:BD9%A()-@;';BV^JFL<#(%%,#J<8\D;1XPV>XM(/&NZWV[(8W^ID
MG@["AP5T=I2B-I8%M0;50@$,:T$7>1V4;`6<C2#.I(I[4ID/C[_;G0-*Z9Q<
M]FV'>W/ECSIXP<7<5W_/-TR;.<N@VVE[E`YZ=JA7ZQF`S$N6..V?2:#MO/4A
M5J0BJ92J(G^H!NP@'7;MHYEXBY%X.V3QQR_>-PVS==MOI[AS!:/-4O)<:5U5
M"D%)@U0<B*4Q*K=6$VU164\C)(CEC0$]2WP/OA_;CG.[99L6HTYR,S6IY!L[
MYG)FN^<4:V)WBJUATA.RC:);1%I10;)2J3ROHM'2@E(`)++G2^?#N/F?E5MQ
M^TW^XM^*W<U]L"LO:GFC,4D@**6+1DDK1RRCW`!]<0<XB64B%BT>5"?LS]O7
MX#[,1P..V&^Y'U2R7(3!.+_%'(N9/'_3M]N^M8[H=@V^NYY+TTMW%@B+>\UZ
M5?0+Y4",8]H+U)#Q2!VBN=!R9)4A2>K^5<B\"^:8=KY+S#>K[8.3V>V0VUU`
MEI).LO:U&L+JK@?,S:":G25#("#78+B;:=S"3W$C0SJ@#`*36GL:'U)_1Z8<
MR],W`/1>!O'&]M-QDZ[([_R(V&T;YKS2GNEW=4JLY:FT>@SI<,Y4$&[X(!NU
M.+AR@7Z*CE<Y$SJI)IJGY%Y]\F[5Y*Y7;2<=25.,;581V5L90!)(D98F5AU&
MLD:5.8502%8E1'[M?)?7"F($0QJ%6O4T]?Z?LZ8\GLIX?;KR3Y2>JO4<F@(6
M8IW%?E0XU39GLI9HN"=PE-47HARO8F/?J$<V!WX0;D?MVP&5[D*';^X!ZK\2
M\[XYQ+AW,]GWN61+_>=F%O:A8V</+2;)F7)!5U^9J#,^V/EA=16]O<1R'YI(
MZ#KUHW^4CK3]F'@E"B9-0H?J8ABA_P"(E$`ZX4,B#B+PS]Z1>'^Z\).'UJQ_
MD+`0M<O4KR+U[16;""LT7:V1ZM;U8`\([/)Q"BK5-RO]@KYHB/U$_$/(`[]N
MNZ_F&YUQSR%SJ'?>+RR2[<FU6T!9XVC/<BUZQI8`T&H9]#Z=,2F[745Y<B6$
MU4(!^HGW^%/\^&ZM-X+>SK@'[$.0W-;UO4C,>3>8<NW#R:U?$M'N;6E2-=L\
MI-DL3]<JLM8ZRV?D83R[UQ$2+5XHJV;RCEHX9'(1-4_5-H\C^(/)OBS:_'WE
MBXO-HWC8@$MKN"(RJ\:IH446.0KJ0(LJ,@#-&CK("2HD8[W;KZPCL]P+1R1?
M=8"N5*>@/IU'N*@X?7X@W_F5=\6G;9S*P;/\6V0MGL)ZSEF9:`TO#%>DH1$2
MYK)9BU*OW,2C:Y"7.];K^"Q6J:9$CB!/(X!YPYSMG`MNY!'9<"W*ZW#8>RG<
MN+B$Q$2EF$FF/2&,:KH85&HDL,Z`XA+E+5)0MJY:*F9(IG4^E`:4H>GPSZXC
MJ\8/03R0VF2Y(\B>;_)??^+F[\C]EO%EM&=\7]8K00<Q19MRO(L&E[GXIO-1
MUD(5Q./63./`XMF<:B0IBB=90I/5/,/S,\3X_%M/%?'>T;9O/&]IL(8XY]PM
MI-:S(`I,*,4:/)$=G^\TA-#103L%SOEO"([>SCCEAC0`%U-:CV!I3H"?CC?O
MT@\&N6WKJ4Y;\<=@C8B5XV.M>7OW&30&-QK\K*34>Y4>5F8//5*-,5_6'MBK
M,#`R"B1DR(I/0=%`/[B]^9?F(\C<(\JC8^5[$[IRQ;$0[A"8G5484D71*WRR
M".1YD!J24T'T.,#>;VUW#M7$65QHHXH?MZ^M#4?JP@UHXR^TCCG[9>9_-[B[
MQAQG=<^Y$TG/*#`DT'?(7.5V\=6ZMG(2,I^.(W>2:+DL]4UFX)+$*4R790![
M"`#LEIR_PYRKPEQ_QWS#>+_;MTVJXGF?LV;S@M))/I754*1HD#5'KEB]]3M\
M^U0V4\C+)&Q)HI/4GUH??#T=[T#FA&<,E-$H^"YW.<U$J/5I@_'UWH+<V>J7
M9>8ABW&I--&6?0;1=K'P*KX[)X=9)-5PDF`@8#>)N`;;MG`9N?#:MQW*ZCX`
M;B1?K1">]V@C]J0P!7(+.$#KI)"D]*5$/&EL;G1(Y%M4_-3/IEZ5ZT].GIAD
M[!>#O.SEC[1<8]B/,KC1B_"6(XYU&79,:GF%WKN@7W=+M(Q]EAXR4N4W7%GK
M4\=#1]G4*=T],F[!NV2:HD5(J=5OZ$Y+Y%\;\)\.;AXLX%N^X<AGW6=29+B&
M2&&SB5HV98DD`.IVC%%2JZF+L05`::FO;*UVU["TD>9I#U(("C+H#3V]/MQO
M7[,.;O)_B[R/]<&0<<:/1-#:<I=VEJ/J-:F6DA*7I2EPJE/7EY&I-H^9COP<
M;!5>6EY-_++H.F[4T>B50"D,<#\W\1^/.'<QXIRO?>5W-S:R;-MJS6\B%5A[
MKB4*LI96UL\BQ1I&"K-K:E2!3!V^SMKBWGEN&93&E5/I6AR/Z0*?UX>-ZX/B
M*PRS[W^%V_\`.WAC5<9XWUV#LU^BN0N<Z$\C[!:8FH,25BMP5X8RCHDI,J)M
M%'"3J;;%*B`_4.4XB`#XCUZ`_+=S_C/C?G\V_P#*Y9(=L?:YX`R1M*>Y(\)4
M:4J:41L^F0'KB7V6\ALKHRSDA#&1TKF2/;&^W+W*+KKO"3D?B=&8LW^A:-QK
MT_-JI&O9%M&,'EML^<S%=AV;J6<B#1BU6E7B9#KJ#]-,HB8?@.N:\%WO;]B\
MA[3R'<69=KM-WMYY&"EF$4<ZR,0HS)"@D`9GIC"M)4BO(YG_`):R*3]@-3A@
MNS^DS7=?]'_'OBC=X.L53G!Q;=W^^Y,[;6N->Q+6R3>IW*R/J.K=HTRC%O#W
M^GRK7S6(8$V<NW9+J&#[4W7IBS_,+L>Q?F(W3FNW233^.]Y6&&Y!C8,42VBC
M$W:;YBT,JM0$5:)I%`^<8FUWB.+>)+I*FTEH&_0H%:?`_#I7+/#F?I'XE;GP
MHX%U7"N14)$U_3X[2=4M$E'PMFC;<R".MMJ7EXMQ^;B5%FCA=PV5\E"^0G*8
M?[OGKD/YAN;\<\@^2IN2<5D>79WM+>-6>-HCJBC"L-#`$`'IZ>V([>+J&\O3
M/`:QE0.E.F&PI'@U[/O6;SNY+<F/7)EV6\H>.W+.==6^[X3:+VQSF5J5@D9R
M2M2I&Z<Q-0+`'5>G9J43B9)HN]*:.E#MW#(#)D5#L,7D;P]Y=\;;1Q'RM>7F
MS\JV2,10WD<)G65%18Q70CFCHD9D1E3YXPRR$$C$D+S;=QL8[:_9HKB(4#`5
MJ*4]CURJ/<=</\<*KQR]T/$T;1S;QF@8-M+RUV,J.=YU;4[I$1U&!5LI4G$G
M-(3,\U-9%6RJB;TB+D4Q.D"@)H^8HI^9?(&W<&VOD)L_'M_<[EQ]84K//'VF
M:;/N!4*(=%0"M5KG2K4U&"NTMHYM-HY>*G4BF?ZA^[X9]<-(?SC_`)%W\C?:
M?[1N+/\`'O\`NL_;_P"1_=D)];_;;^0\/SWE_,'Y+O\`A_\`6_(_:_D?K_V?
MB_\`V>NX?X=_*M^%:_QS>?Q3\%UZ>V]/KZ?<_P"ET_>RT:NW3/O>N)3L[#VZ
M]V3N=NO0_>_[/[.GQ]<2)>O+&(+!TPP=,,'3#!TPP=,,1^_;QZ.<XYV1\WN.
M$)P.6\N6+$SA=^=(L=2=Q(R0`J$%HI&J1@C;0**8),+$FF=9/L5%Z5=N"9FW
M9O&OEJ^XBZ;3O&NXXV32G62"O]J*O5/5HB:>J4:NJADU9CKB#-G>6Z-B?+:`
MRG7*7/9[H])M<A$VBH65D9E+13PD%+&3,)>YT'L>]0$JS5VW.JU=MSE51443
M,4P^R+/<+'==O3<=ME2>QE6J.IJ"/\A'0J:%3D0#C6>5"G'[H'_AC^^N)(W"
MW@;JG,:RE7BR+T[(X=^5O;M/?LC*-"'2$AG,%4&JOTT[%9Q2-V,4IOM67D!G
M!P$2)*:%SOR)L_![33-2?>G6L<`.>?1Y"/N1_P#Q-T4=2.6[#QR\WR:J52R4
M_-(1^Q?])OV#U]C+MP7CYE7&J@1^<Y+6D(&$:^*\@]5$KJ>LLK],J;B=LTN8
MA'$M+.O'Y.;Q33+V32(FD4I"^+.1<EWCE6Y-NF\RF2X.2CHB+Z)&O15'MU/5
MB22<=LV[;+/:K86MD@6,=3ZL?=CZG_V"@PM74#C/P=,,'3#!TPP=,,'3#!TP
MP=,,'3#!TPP=,,'3#!TPP=,,'3#!TPP=,,'3#!TPP=,,'3#!TPP=,,'3#!TP
MP=,,'3#!TPP=,,)S*9#ELWIU5VF7S^I26MT:N6"H4_1GD&P7N-;K%J6:+V*"
MAYY1$7[*,EU6*8K)$.!3=C?H!S^4K#OF\6^T3;!!=3ILEQ*DLL`<B*22.H1V
M2M"RU-"1[>PI6)'"&,$Z#U']/Z9#VPHW45BC!TPP=,,'3#!TPP=,,'3#!TPP
M=,,'3#!TPP=,,'3#!TPP=,,:*\L_7)Q7YGVO,-`V2D+_`,AY--MW];OU3?!7
M+8^KX?<%E*!8Y9NW56FZ3,)NU!,V4[+,UC"LS6;*F4,?=>)\_P"2\,6:+9IA
M]-,I!C<:T#TH)54F@D7T/1NCAA0##O[&#<;5[.YKV7H#0T)`(-*_&E#\.F-R
M*C4:O0JU"TVEP,75ZK7&",9!P$*S181D8Q0`03;M6J!2D(`B(F,;Y,H<PF,(
MF,(CJE[>W>XW<E]?R/->2L6=V)+,3ZDG^@&0RQ?@@AMHE@MU5(4%`H%`!\,9
M%UBXNX.F&#IA@Z88.F&#IACH=.FS)LX>O'"+1FT05=.G3E4B#=LV;IF57<+K
M*&*FBBBD03&,80*4H"(CVZJ1'D<1Q@M(Q``&9).0`'J3Z8`$F@ZX0>4Y6<:H
M;):KO,GNN6-<7O+IBPIFHFN<&I1[6^DOR`,&=>L*+M2.EW;H8EUX)H'.<1;*
M_']ANVRP\*Y=<;W-QJ';;UN06REI;?M/WHPNG470C4H&I:D@#YA[C%\6MPTI
M@"-WAU%,Q]HQ?ZAR"PW0/X^_8^N9W;!UB*M<WF85^VPLJ-[BZ(X8-+LZJP,W
MBHS(5!U)H)29$/-1@HH!5BD-W`,6^XOR/:_JOQ&QNH/HGC2XUQ.O9:8,8A)4
M?)W0K&,F@<"JUQ2\$T>K6C#20#4'*O2OV^GOBX/MLQ^,:M'TEI]$CV3_`$Y#
M%&#M[:(=JV?:^YECP#?,F2Z[M-)W>EIQ([,L6F)G@NB&2^GYE,4+4?'M]F=H
MX;.Y:1;,W9`C8D6H76;@@#*$)1NX?ETD-6A!P$,I-`K$Z=73^SUK]GQQW2>R
M9/"OM&C);2*3&R605J,N>J1[VR1+=]GE1FF4M)1%FN+15T5>O04FP@'RS=TY
M*FBJFS6$IA^F?M3#L.]W$=I-!:7#Q7\S16S"-B)Y4*JT<1I1W5G0,JU(++49
MC'P12MI(4T<T7+J?8>_7&(WWE%QSRV\U7,]&V[,:5H-W4BDJM3K'<(6,L$N:
M?D"Q$`9*-<NR.$$I^6-]HP.L"9'KH!21$ZA1*&=MO#N5[SMTV[[5MUY<;7;A
MNY*D3LBZ%U/\P%#H7YG`J47YFH,\5I;7$B&2-&,:]2!EEU_5Z^V,K<;3D+21
MCHAWIM%:2DOH[C'HI@ZL\.W=26K-(%S:7&<,45G9#NKLE7&:KT8T@"[%LF8X
M$$H=^L->/[Z\3SI9W+0QV@NF81L0ML7$8G)`RB[A"=P_+J(%:XH$,I%0K4"Z
MNG]FM*_97*N+-;^1.#Y_5Y>ZW;7\[JU3@;BZSN7GINUP[".97UBJ=%[2U%EW
M1?.T-#I'%5@0#.4RIG,8@%(80OV/%>2[G>1[?M]C=37LMN)U1(V9C"142T`_
MEG*CGY34"M2,5);SNP1$8L16E/3W^SXXRRF:?G.BT9CIM!O53N>>23%Y),;M
M6)^,FZPY91JCA&373F8]RX8]HMPS62=%$X&;+(J)J`4Y#%#"O]GW;:MQ;9]S
MMI[?=48*8I$9)`6H5&A@#\P(*Y48$$5!!Q0\<D;]MU(D'H1GA+*#R_XM:G`W
M2SYUR!R6YU[.:P:[7N7K]W@I!C4Z:1I(/QMLXLB\$&%9^SB72@/S]FHE;J=C
M_P!ANTSN?!>9;-<V]GNNUWUO=7<W:A5X74R2U5>T@(^:2K*-`^;YAEF,79+2
MYB8+)&X9C05!S/M]OPQ32N8/%C1HFRSM&Y!Y):(FF_@#6M[$7B!<IUY.U2:<
M+6G$N4'@*L6L_,*E:,U5"@DX<_Z1#&.`E#[N'!.9[5/#;;EM=]#/<:^V&A<:
M^VNN0+EF44:F`S5<R*8/:749`>-P36F1SIU_5A4Y[4LUJO[T_<]^IU<+G%:C
M+EH"L]8XF';TJI31IPD39;2XD';=""@Y$U:D`1=.3)HJ"R6[&_TS=H6VV;=K
MWZ?Z.VGE-W,T4(2-F,LJ:-4<84$NZ]Q*JM2-:Y9C%I8I&II4G4:"@ZG+(>YS
M&$TK/+?B_<<^NFK5?D!D<UF^<$(>_P!U97NO'KU+(JW3=MC6>1,^(C"%>MU2
MF;_<"G]P!@^EYB/4O><'YC8;I;[+>;9?1[M=_P`F(POKEH:'MK2KT(^;373Z
MTQ=:UN4D$31N)&Z"AJ?LQGN<;)E&OTU30LLT6G:#2$7,FR<6BHS\=.0[1]#?
M_-F#UVP76(R?QH=A605\%4RF*8Q0`Q1&-W;8-[V*_&U[S:SVNXD*1'*C(Q#_
M`'6`8"JMZ$5!SSRQ;DAEB?MRJ5?V(IA':=SGX<:$M9V](Y,XQ:%J3!.[-<4X
M:^P+P:M`,%(Y)Y+6#Z;L0B&;8\PT\S+_`$^P.4Q_0Y1&=O\`QSSS:UA;<=HW
M"%;B01Q:H7'<=M1"IE\Q.EJ::_=/L<7GLKN.A>-P":#(YGX?JPJ^@[ECF3M+
M(^TO3J316E/@JW9K2M9[%&Q!8"O7&RN:;4YF4!VNF9I'V2V,E8UBH8`*Y>IF
M13\E`$O4+M?'-^WMX8]HL[BY>>22.,1HS:WBC$LB+09M'&1(X_LH0QH,6HX)
MI2!&K,22!0=2!4_J&?V8Q6!Y6\9[/G-OUZ!WK)I++\^%0M[OJ-[KI*O3#IIH
MJ^%IEEGZ36!452<I&2*Z,D*P*D$@&\R]\VYX5RZSW6#8KG;+Y-XNOY,)A?N2
M]1_#4+5Z4-=-:4-:4.*FM;E9!$R/W6Z"AJ?L]\>ZC\F>/.EUUC;,_P!KS&XU
MR1NS+-6DO7KE!RC130I(J:D=1U#-7BAF]K?HK)J(L%`(Z524(H4@D.4PVMQX
MARG:+IK+=-OO+>[2W,Y5XG4]A?O39C.-2""XJH(()J#CX]M<1MHD1@P6N8/3
MW^SXXOMOW+&<_A+W9+SJF?T^OYA(QL-H<U9K9"0D93)F9BX:;AH>Q/)%XW0B
MY:9BK%'KM&RIBKNB/4/I%.*I`-C6/'-_W.XMK3;K*ZGNKQ&>!(XW=I51F1V0
M*"6561PS#)2C5(TFGQ(9G*JBL6;I0=?3+]1QX:/R%PO2X.LV3/\`7,]N4%<K
M6_HE7DZ[:H>4;3=VBXB5L$E46!FKI0REE8P,&[>JL>P.2-&YUA)],/+J[N/%
M^1[1<36FZ6-U;W,$`FD5XV4I"S*BRFH_EEW5`_W2S!:URP>":-BLB,&`J:CT
MZ5^ROKA1X:R5^Q*324#,QLPI7)MS6Y\D<\0=FAK`R;,WCN&DBHG.+.2;-9!!
M0Z)^QRD6((AV,'43<6EU:B-KF-XQ+&)$U`C4A)`=:]5)4@$95!Q059::A2HJ
M/LPCM.Y4\:="OTSEE$WK)+AH]?\`S'YBE5R_5J8L;,:XH5&QD&,8R*SA=2N+
MF!.0*D!S,5/[5P3-\=3U_P`+Y=M>V1[UN6V7T&TRZ=,LD,BQG7G'\Q4`:QFE
M::QFM1BZ]M<1H)71Q&?4@TSZ?K]/?"@*ZEFZ%;IEQ6O551J>BOJK&42RJS<>
MG!6Z0O7T?V6R@)0ZX,I-S;#N4B1Q$CF,\453(EY'.4!C%V;=FN[BP6VF-[:K
M(TT>AM<2PU[I=:541T)<D?(`2U`#BWVI"Q32=2UJ/:G6OV>N,;N7(3"\[B[E
M-WO7<[J$1GLW#UB[R-AML+%-*O9[#&L9B!K,PL[>)$:629BI1LY:L#?]VNBY
M2.1,2J$$V78<7Y'NLUO;[;8W4\]U&TD*I$[&2-&*O(H`SC1E96?[H*L":@XJ
M2">0@(C$L"10=0.I^P>^,<F>67&.O9A6=IG-]R6+R>YR'XBH:`\O5>1K%HF`
M6?MU(:OR9GWT9B9;KQ3HBS1O]1PB9JL"A"_24\<JWX3R^ZWB;C]OME\^]VZZ
MI81"YDC6@.MUI54(92&:BG4M"=0K4+6Y:0PJC&4=10U'VXZK-RZXN4W/*;K5
MGY!X_#9EHBBJ5!O3J_UO]L715LW=NW:=7EDI!1K.G8-F"YW`-C*"W!$_U/'Q
M'M59\&YE?[K<;'9[7?R;Q:@=Z$0R=R*I`'<735*D@+JIJJ*5KCZMK<O(8EC<
MR+U%#4?;[8]NB<J.->2UJH7'3-XR:CU70&`2U&L%COE<C8JX0WV+:4/-UMXO
M(`C,P:,:]074>MQ4:I(KI'.H4JA!-;VKAG+=\NY[#:-MOKF]M6TS)'#(S1/4
MKHD`6J.6!`1J,2"`"0<?([:XE8I&CLR]0`<O@?CB_6O?\0HL):[+<-8S^N5^
MBP]-L-PF96TQ#6.KD'HCY>,H4M+.SNOHM(^YR+91"+5,/@^5()41./QUBV7&
M.1;C<06EC974MU<R2I$BQL6D>`!IE44J6B4@R#J@-6IBE8)G8*B,68D`4ZD=
M?U>OMBP4_E1QNOT9`3-.W#,K!%6J_IY569!C;X<6MATM:`=VE"APJJKE(LE;
M'%=8+O$V"/FX4;I&,4H@`]95_P`,Y9MDTMO?[=>130VOU,BF)JI;AQ&9G`'R
MQAV"%S10Q`)Q4]M<(2'1@0NHY=!6E3\*Y5Q=[OR*P;-JQ+W2_P"PYS3JK`W(
M<[EYZQ6V&BXYE?B@4QJ4HNZ=I@>U%3-YBP)Y.@3*8_AXE,(6-NXKR7=KQ-OV
MRPNY[V6W[ZHD3LQA_P"+0#^7Z:S\M:"M2,?$MYY&"1HQ8BM`/3W^SXXP2Q\V
M>(=2@,]M5CY)8U%5S68)_:,RFG%^KYHZ^5R*68MI2;JKE%ZJ2:BXQU)MTG"R
M'F1!58A#B4Q@#J2M/'O.;ZZNK*TVF_>[L95CN$$+ZH9&!*I("/D9@K%0:$@$
MC+%:V=T[,BQN60T.1R/QPGFG^Q3BWE\Y0:VK;9S0)S1ZK$7VO1N2U.:T5S^P
MI\RY82WN25]NN*K&;*U6.P9M?N9>1304.T9KE3.(2NS^*^9;Q;W5VL$=K;6D
MS0NUS(D`[R4UQ#610I4!V;3%&2`\BDC%R+;[F568`*JFAU$#,>F?[?0>IQM7
M_)E!_CC^7OW9#?QG^S_W_P#O7[D/P?[-_$_G?W!]SX]_L/Q/^OW\?+Q^.W?X
MZTK\(W/\6_`NQ)^+]_L]JGS]W5HT4_TM66,7MOW.U0]RM*?'I3&<]1V*,'3#
M!TPP=,,'3#!TPP=,,'3#!TPP=,,'3#!TPP=,,'3#!TPQIA["VMTD^&N^0%(E
M5*NO:*,_K%OOR4>\FULPRB=,G'['IS6M0ZR=EMLG1,L6EY!C$Q!59:2?HHMV
MI/J*`8N_^+7V^'GVV76XH)EAN5DBA+!!<7*?-:VYD<=N)9K@1(\LM(XT+,YH
M*'+L"@NT9Q4!J@>[#[HKT%6H"3D!UPT;E3R]YTRSEI0&56Y&8'$^Q2FV_C?8
M,#@X;(ZW;).PX!O4#M^34"F:;I+J'@V>>Z)"/)LTFK8!@912:>)-78O&RS)/
MN&]1[;NLEV^Z--M7)GXK+%?I>N]S)&J7MF]I<S2V\`9S/`Z0]L0]Z,11ET[;
MK(9601R%M=8YS;D.&.HBC*58D#U!I2E105%#7&3N57[S]\Z=FS&)B^<#CV17
MJ_8'QIE),RD>TT&&XO5JKZ_A<]I-<BY'.$"W7`6,C:+?+Q,J^K$9:7Z#!Q)*
M3#<Q#XB+%']-L^[,[^.QQ.&&]OU7YC`^X226MXD$C+.>U>E+>UBDC2XDMT:1
M8A`P(IR&F.2IL_IP&?X:R58`YY/15!`8J*TIC"-^H<%8<PXOYZ._4O-..=3R
M_7&4/R#T+(;UI<[K'L"L=MGX2XRE9S1A8:-<Z/O.?VFOVJ;B59-$9!U8)]1K
M%L'KELL"$CQG<KFUWC>-T&V7%WRJ>\MBUE!=0VZ6VRQQ(\2R7#)-%-9SQO;Q
M2",Z%AA#S21HZZJX'*R2R=LM<%EJH8#3$`*5-""I!4&F5!4D5PE7+EC:;%=.
M;5F2FJUGW.N'X4T>9U3-10L$[5+AQR>82\KW(REW.S5:-EZO!PD3:9$D_0))
MTX*X5L<<1LV*<KB50+,\&DLK6PX]9F.:Z\<2<@F2WGJB2Q7PO`]C+%'(RR.[
M1J8;V-5TB"0NY!6%L7+0HJPK0M9F8T.0(;55"`<^F3#V-?;&_L[=I&D:?['*
MW6\6RG;(JXZ%C<SH>A:O>*+1LJR@93C[C];:4[DC%:9)Q=PEJ!4H&$2LD*\J
M,788R6":7CTE&DFV?"3F=MM\6X[/Q2[N]PO=OF@M;I((+:&::YN=-[=2&6P:
MW5HEFE=S!*ES)!)'VEE(>%XZX2H'BMV9V0A6H%!+-\S&J4RJ3D=1!%*YBF-;
M^1T/BLPF]B=[M;VI4*5]LVRL65JJ;.T/[Y6--D.'=C98[-Y<PJT#-V9[JD#J
M:T0\KZ,>U=K*OTDB%(L`G3-MG%)^06Y6?C,"S[FG"+4F.4QK#);KNB&Z2X:1
MTC%L]N)4F+LH"%C5<B,BW,PS@%9!:KD:4*]P:JU(&DK4&OICT8>XUVHW_&IV
M_L*7K/(N%Y/>R6HS=-SIQ#U6>N,[((Y_&SNNX6YU@T)E<;<H6(@D9!W`R\NS
M=!#SLHFP,\18O$3T<B78[[;-PMML:XL>*R;/L,J2SAY$B13,R6UX+;7<M$[.
M46:*)U[L,)ET-)&P^2]MXW"U2`QQ$$Y@"K45J?-0^X!%0*]0<.$<5FF@I<2.
M0QM.D8A:??7[DVX*D53%W%NAF9EY9NNRV%?CK!0^5+;`$N@[<V$(Q-TJD[7^
MDY77=$6,/+^9OMC<XVL;0D@MEMMO%?\`\L1.:*0;47SM<BUTE5@[A4%15%5"
MHQ@W)C^JC[5=.E/]*A_V=1U:?:O[L-VO+)8;SQ^S]*U9T.+N*9Z8.2,15WUI
ML50LMVV&#FL<Q5L]LL'&9E(WEO5<PI:L*U=">TNHR3?R$R@DSBS';O3)]3CM
M+7;N3W365W^()<<_L&D$:2QPVKI=79$;M<+"9+B4.RTMUDC1(F:28!HP<_2J
M3MI;6&O$K0$!2&;+.E6/^K4`#,YC'MY"4FTT6]<D*Q==ALFVVRS\0,>NF=:3
MLD*2I/<V=4?D+01B<76A,USJHU*?HVW:,O%__D,1&OI.OOD%RRW@V%HH>WQ?
M<+/<MMVF\V^PBVZRAWVZBG@M7[HG$UE-JNP\\\LJ36D`D_@2R)'.A4P5?6!\
M@=72-D0(HE8$+G6JGYLR2"HKD30CIZX4C?+);+E8.6-XO&;(Y/88-UZMG\=B
MNM6RNR9+V:G\F]*GJ]7K];,Q-I&9U&GZS:WAH*/>.Y9RU8/68.IPD='G(HI$
M\9M+*PM=DV[;KLWMK(.0JUW;1R+V>[M]NCO#'<=BXEEMHQWG18U9T;1;&64$
M"W`JH(D1M2GO?,H.54`J`:$E1F<LQDM3C&-[G]J(]Y?WW7\_L+S.EJ]P_&MX
M;>K9@<-R>0NDEREF5ZD&36_B&VL=P:-:TN\;I9:%KF9`SV[,W!5C%:*NG(YG
M&;;CYCV+;-BNHEW42[IW+R&*\?;S$NW()?J8MS,<1,@!.X_31)HM&4K5PB8J
M@6&D21,.Y5ZL`VBFC/4'H,_[=`/E^.6'"O7\&CFKNWN+^,^BDYUQDI7HW51R
M1?DO&L@RS.BJH\CI#%R(5AW<%$P0-#!()?N%.K#&A(**"*/CR[R=^$BZVY=L
M[186)UM;?4BP8_4ST-BMW601=1+H/8-QW>T!\U<&^[>I-%/N9Z=6C[Q^YJSI
M[TRU5IC0;1FI5LE]]B)Y(S4KS<H@AW;$K\7\6*G$/C"C]9`$XQTH:303\56X
M-TG?]_T_[3&[DZZ9M3Z=\\:,$U:=N;)J:6_\SW`T/S#Y3T;45RKF!GC.C/\`
M%L<O[!_\1\6S8J`I':CLM>@MPY#3DE.P7JX287S9(9R&C4I^M[%YMNT=4J-M
MV2UV'?-&BWBNU*YBY-H>0\BK@*?<O5W8=S$NSV%U<[=M4<,<G(2T-JX[$JC8
MT)$K17+L"1DVF2-@E-.>>/L+UC1F2,`&;)>A_A>M&/Z<QC&;)!O<^UGD+`6^
MWEW[4Z-S$X4:@SO&SE2H<SM\+-0^BM<JXS66/;TJMYE192C2K.:=TFRDC&E+
MFI=VQ1<OFLD#@Z&9:7";ILFUW-C!^&;-<[#NUN8;7^,EHZ-`;G<(V,LEQ,LR
MF);NW[C7<42R,D;Q:0U2D211L@[<;0R"BYZ2"-3C,L:Y:A74!6@(QG&KV2PV
M;>]3T]/.$\[UNN[OZX$&G&R;LT')VS1'M9M&O2,9)S]YH#RWXA4]9T.M6:0C
MH1D[L1OH1E7C%9US&LY-@=*.V6TM;3C-ELYNS=;)+MN^DWZ1NL<`DCM594AF
M$5W+;021H\KK!G)<3+;),\,@:B)56%8RVJ(QR_.!D*A>@-&*@@$Y=6.FI!Q<
M;=9;$ZTN8U2R9O$1MV8^T/*)9IQBO-HK:]LGI$G`B.HU:KJEY8.G.$P^KGAU
MPNU937M"L`HLV:1JTHA-+IM4;5C:6J;1'LMI=N^W-PZY4[A#'((T7\9::1^R
MP%XUMK'TEP5MQ,`SRK"UNI=J551$(E8E/IF^<#(?Q:DT^]IK\IRKU-*9XP0]
M=W*QZ<D7;;SI6?QDQ[!,\"E'IY<%E.7E7+&\$=Z//K:<;BEG=HJIY*P(+,"1
M*#].6E$J<B05UT2'3'J2%WQVTV<GCUM:74T?%Y^[W?K5VR35O%GH%O\`B,\<
MFE"',I0Q1FZ)TJQ!Q7JA6/\`@JK$0&M=7;/\1:4UD'+.M*#5AR#A?`!%9ORD
M@6MWTFQ"7D5K#=*[Z*PF3:><[FBT,22$Y'+UBH2RLK'"J'VJ2<<@<[9-`$_,
M1`YN4>0+DS;MLUR]O:1?^56Q[,#)]/E--\J,))5TM_:)<@,6K3H,"[:LD344
M?PUR%*=3\3^_&B/&B4U6:8^LZ,@:G7Z;B=.SYQ7ALBMEXQ3>,:M'P?';1V+6
M_<=V4C&.>7<;K-Y?NVSZ39.FU<<Q<,VE$99N=Q]85^D<NAV6WDY=-<SRW'(9
M[H/VQ'N"75LSWT!,-\58;8UM"H9(W5IUDE:%H&"Z=.;<B)3<DDF8M6E'U+\X
MR?\`W>D>G6II3"P4RXUVV>J,M>Y#Y);\NRF`X>Y5'15[M4]G\Q'WF9-2(-E0
M)_-6.8W2Z:'&V8EX:P[R`3>Q$=,_E'+$K9N9Z44B06X6%W8^:OJN+7T%YO4N
M_7+-#&DRM"G><S)<&XBB@:/LF59BDLD7;60NW;.HV61EW/5;N&E,IR`.6>=:
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MIIPQBN.<K(QH0JS)582MZBY63!J?LW46(DD/8,S8`@W;:HYC(8A><I#/N2G4
M1]"@+7RJVL&GS7*@ZA\P4LV*HOYD8-::KC[_`/L#[_\`WL4<J`SRT8+Q4C.5
M?^ZW-*&OS=E(M&P\BW$3-\AV-NDN-6W(Y/9<B1PR/LTJK:*]J[J*5J:#=B>3
M5FFH`1%<IBE4^\,_%+/DV]3<+_!;O<AQU6*6(9+$Q+?VAN8[DWC1J(WMA(+E
MF<1B)LV4@D+;N+/*;7M-)V1DF2TUKJ#:J"A6NK.E,>'''.WT/6L*M6A1D1N6
MYU?E?SZI=NS?.'</26&DR#ZEYJT_FJB.M)&N9Q$:'%0-7;.E*X^L<0X)%VF<
M+&F>ECEDAN;\G'=RV/<K+:WDV[CDVR;-+%/.'F,"B6X/TDP@USM`SR,HG2"5
M>Y;V_=$9E5L)>U)$ZI_#A,49!-305;Y33.AKU`.8%>M<6#4[+;IKDIQ*M$+F
M>GTNQRV%<_59O,/79<\MG[14UG')S"SR:%VM+ML?-9F=:2*1"WD(]P<2798Y
M4%'*::BQ\K9K2QM^);W9W%Y9W%HFY;+HN-\BN$CD`V^\TF*,'ZA4*D_2:USM
M`"P0D**XE1;>52RLH>*AE!`/R-T'6G^C_JXNFYUC*I#D'3K7+:#8XO2)QGB[
M1]E6OA>X;0*%O[6O<>#5&<UFW9CE^ET"X4^6@V5/)/QYUVL0VEW+LY71E552
M1]GCEYO47%[BR@M8GVF-KLK<VO9:":R+WW=2VBN+BWFBE5S=&%P&E:)4!0``
MRTPM*("H4&,:OF6E"E7J%!((/WJ'K2GZ7;_VY3?]HG[:_D9M^*^P^S_DS]JO
M_P`-_(7[]\OSO[,\/N?VG_*/_P!/^I]#\9_I_<_0_P"YZX?]7?\`^.?J_I#W
K]5?I^XNOL=G[G=Z=SZ?^W2O<ST:ODQ%ZG^JU:<_:N=*=*^]/7W]/3'__V3\_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
